Methods | Randomised double‐blind clinical trial. . Women were divided into a control and an experimental group in a The trial was conducted in the United States of America. |
|
Participants | 81 normotensive and 34 medicated hypertensive women. Age: between 35 and 65 years. |
|
Interventions | Intervention group: 3 daily tablets of a calcium carbonate supplement containing 500 mg calcium‐tablet . Control group: placebo tablets. Trial duration: 4‐year. |
|
Outcomes | Bone mineral content and blood pressure | |
Notes | Most of the women were using thiazides "Dietary calcium of all women was determined using a precoded food record form, which had been tested for validity against weighed food intakes." This study was supported by Wisconsin Milk Marketing Board, Inc, Marion Laboratories, Kansas City, MO |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Not described |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | "The original group of women, including the hypertensives, was divided into a control and an experimental group in a double‐blind design." However methods were not described. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | "Blood pressure was measured from the right arm of seated participants using a standard mercury sphygmomanometer." Not reported if outcome assessors were blinded to the intervention. |
Incomplete outcome data (attrition bias) All outcomes | High risk | 44 participants were randomised to the intervention and 41 were analysed. 51 participants were randomized to placebo and 40 were analysed. |
Selective reporting (reporting bias) | Low risk | All primary outcomes were reported |
Other bias | Low risk | Baseline characteristics were similar between the groups. |